New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat...

Related Keywords

United States ,American ,Jonathan Graham ,Michael Meo ,Marlena Abdinoor ,Sloan Simpson ,Angelika Jahreis ,R Sharon Chinthrajah ,America Julie Masow ,Prnewswire Novartis ,Parag Mahanti ,Robert Wood ,Eudowood Division Of Allergy ,Johns Hopkins Children Center ,National Institute Of Allergy ,Asthma Research ,Genentech Inc ,Inspection Service ,American Academy Of Allergy ,Novartis ,Seann Parker Center ,Drug Administration ,Stanford School Of Medicine ,Exchange Commission ,Consortium For Food Allergy Research Co ,Novartis Pharmaceuticals Corporation ,Development Unit Head ,Genentech ,Roche Group ,Public Health Impact Of Parent ,National Institutes Of Health ,National Institutes ,New England Journal ,Eudowood Division ,Johns Hopkins Children ,Associate Professor ,Stanford School ,Secondary Endpoints Results ,Pediatric Population ,Key Secondary ,Additional Secondary ,Adjunct Therapy ,Food Allergic Children ,National Institute ,Infectious Diseases ,Food Allergy Research ,Novartis Pharmaceuticals ,Important Safety ,Important Safety Information ,Food Allergies Among ,Public Health Impact ,Parent Reported Childhood Food Allergies ,Accessed November ,Food Equivalents ,Food Allergy ,Environmental Factors ,Accessed February ,Dna Novartis Pharmaceuticals Corporation ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Fda Approval ,Surveys ,Olls And Research ,